Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

BIOLASE, Inc. (BIOLQ)

Compare
0.0100
0.0000
(0.00%)
At close: April 9 at 4:00:00 PM EDT
Loading Chart for BIOLQ
  • Previous Close 0.0000
  • Open 0.0130
  • Bid 0.0100 x --
  • Ask 0.0130 x --
  • Day's Range 0.0129 - 0.0130
  • 52 Week Range 0.0040 - 0.2000
  • Volume 20,200
  • Avg. Volume 108,567
  • Market Cap (intraday) 365,973
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 0.00
  • EPS (TTM) 17.2000
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 24, 2005
  • 1y Target Est --

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. On October 1, 2024, BIOLASE, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on February 24, 2025.

www.biolase.com

157

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIOLQ

View More

Performance Overview: BIOLQ

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIOLQ
16.67%
S&P 500 (^GSPC)
7.22%

1-Year Return

BIOLQ
93.71%
S&P 500 (^GSPC)
4.74%

3-Year Return

BIOLQ
100.00%
S&P 500 (^GSPC)
21.58%

5-Year Return

BIOLQ
100.00%
S&P 500 (^GSPC)
95.60%

Compare To: BIOLQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOLQ

View More

Valuation Measures

Annual
As of 4/8/2025
  • Market Cap

    475.76k

  • Enterprise Value

    15.72M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.01

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.34

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -34.84%

  • Return on Assets (ttm)

    -24.09%

  • Return on Equity (ttm)

    -1,241.25%

  • Revenue (ttm)

    46.03M

  • Net Income Avi to Common (ttm)

    -15.97M

  • Diluted EPS (ttm)

    17.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.44M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.68M

Research Analysis: BIOLQ

View More

Company Insights: BIOLQ

Research Reports: BIOLQ

View More

People Also Watch